A Population Pharmacokinetic and Pharmacodynamic A Clinical Trial in Cancer Patients

Clinical Pharmacokinetics

57, 335-344

DOI: 10.1007/s40262-017-0559-8

Citation Report

#	Article	IF	Citations
1	Extrapolation of pharmacokinetic interaction data of proton pump inhibitors obtained in healthy subjects for oral targeted therapies in cancer patients. International Journal of Pharmacokinetics, 2018, 3, 93-97.	0.5	0
2	Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate. Bioanalysis, 2018, 10, 1229-1248.	1.5	17
3	Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling. Clinical Cancer Research, 2018, 24, 6028-6039.	7.0	41
4	The role of abemaciclib in treatment of advanced breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692.	3.2	14
5	Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer. Annals of Pharmacotherapy, 2019, 53, 178-185.	1.9	27
6	Pharmacokinetics and Metabolite Profiling of Trepibutone in Rats Using Ultra-High Performance Liquid Chromatography Combined With Hybrid Quadrupole-Orbitrap and Triple Quadrupole Mass Spectrometers. Frontiers in Pharmacology, 2019, 10, 1266.	3.5	5
7	Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. Cancer Treatment Reviews, 2019, 74, 21-28.	7.7	31
8	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societaâ€™ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2019, 140, 39-51.	4.4	11
9	Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Research and Treatment, 2019, 176, 483-494.	2.5	28
10	CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors. Cancer Chemotherapy and Pharmacology, 2019, 84, 447-452.	2.3	19
11	CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib. BioDrugs, 2019, 33, 125-135.	4.6	75
12	Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma. Frontiers in Pharmacology, 2019, 10, 1316.	3.5	3
13	Drug Exposure to Establish Pharmacokineticâ€“Response Relationships in Oncology. Clinical Pharmacokinetics, 2020, 59, 123-135.	3.5	5
14	Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses. Journal of Pharmaceutical Sciences, 2020, 109, 1169-1177.	3.3	5
15	Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. Clinical Pharmacokinetics, 2020, 59, 1501-1520.	3.5	43
16	Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 523-533.	2.5	7
17	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 5310-5319.	7.0	102
18	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. International Journal of Molecular Sciences, 2020, 21, 6350.	4.1	34

#	Article	IF	Citations
19	Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer. Drug Metabolism and Disposition, 2020, 48, 796-803.	3.3	8
20	Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. Journal of Clinical Pharmacology, 2020, 60, 915-930.	2.0	34
21	Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. Clinical Pharmacology and Therapeutics, 2021, 109, 494-506.	4.7	16
22	Therapeutic drug monitoring of oral targeted antineoplastic drugs. European Journal of Clinical Pharmacology, 2021, 77, 441-464.	1.9	110
23	Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. Investigational New Drugs, 2021, 39, 272-277.	2.6	12
24	Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report. Molecular and Clinical Oncology, 2021, 14, 61.	1.0	1
25	Simple and Rapid Method for Determination of Abemaciclib in Human Serum using Supported Liquid Extraction Pretreatment and LC-MS/MS Analysis. Indonesian Journal of Pharmaceutics, 2020, 2, .	0.6	0
26	In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. Breast Cancer: Targets and Therapy, 2021, Volume 13, 87-105.	1.8	5
27	A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Investigational New Drugs, 2021, 39, 1089-1098.	2.6	19
28	Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer, 2021, 28, 1038-1050.	2.9	10
29	Quantification of abemaciclib and metabolites: evolution of bioanalytical methods supporting a novel oncolytic agent. Bioanalysis, 2021, 13, 711-724.	1.5	8
30	CDK4/6 Inhibitors in Melanoma: A Comprehensive Review. Cells, 2021, 10, 1334.	4.1	31
31	Myocardial dysfunction caused by abemaciclib: a case report. International Cancer Conference Journal, 2021, 10, 324-328.	0.5	3
32	Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs, 2021, 81, 317-331.	10.9	173
33	Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6â€“Cyclin Dâ€“Rb pathway. Cancer Chemotherapy and Pharmacology, 2022, 89, 31-40.	2.3	7
35	Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients. Prague Medical Report, 2021, 122, 243-256.	0.8	5
36	An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum. Journal of Mass Spectrometry and Advances in the Clinical Lab, 2022, 24, 15-21.	2.4	3
37	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nature Reviews Urology, 2022, 19, 305-320.	3.8	9

#	Article	IF	Citations
38	Pharmacokinetics and therapeutic drug monitoring of anticancer protein/kinase inhibitors. Therapie, 2022, 77, 157-170.	1.0	2
39	Abemaciclib in Patients with End-Stage Renal Disease and Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Report of 2 Cases. Case Reports in Oncology, 2022, 15, 305-311.	0.7	2
44	Identification of Novel Mutant (R132H) Isocitrate Dehydrogenase 1 Inhibitors for Glioma Therapy. Journal of Computational Biophysics and Chemistry, 2022, 21, 647-661.	1.7	1
45	Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. European Journal of Clinical Pharmacology, 2022, 78, 1239-1247.	1.9	6
46	Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment. Pharmaceuticals, 2022, 15, 614.	3.8	14
47	A New Lc-Ms/Ms Method for the Simultaneous Quantification of Abemaciclib, its Main Active Metabolites M2 and M20, and Letrozole for Therapeutic Drug Monitoring. SSRN Electronic Journal, 0, , .	0.4	0
48	The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?. Cancers, 2022, 14, 2709.	3.7	2
49	Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation. Oncotarget, 2022, 13, 864-875.	1.8	6
50	Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. Oncologist, 0, , .	3.7	11
51	â€œA new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoringâ€• Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1207, 123403.	2.3	4
52	The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels. Biological and Pharmaceutical Bulletin, 2022, 45, 1476-1481.	1.4	2
53	Imidazole and Biphenyl Derivatives as Anti-cancer Agents for Glioma Therapeutics: Computational Drug Repurposing Strategy. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 1085-1101.	1.7	2
54	Effects of<i>ABCB1</i>and<i>ABCG2</i>Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18). Anticancer Research, 2023, 43, 1283-1289.	1.1	3
55	Abemaciclibæœç”¨è»¢ç§»ãƒ»å†ç™ºä¹³ç™Œæ‚£è€…ã«ãŠã'ã‚‹å¥½ä¸çƒæ¸›å°'ç—‡ã®ç™ºç¾ã«ä¼´ã†è¡€æ¶²å¦çš„ãªå¤‰åŒ–ã®æ¤œè¨Ž. Journ		
56	Abemaciclib does not increase the corrected <scp>QT</scp> interval in healthy participants. Clinical and Translational Science, 2023, 16, 1617-1627.	3.1	0